Abstract: Described herein are chimeric polypeptides that include one or more Rubisco-binding motifs (RBMs) and a heterologous polypeptide. Additional aspects of the present disclosure provide genetically altered plants having a chimeric polypeptide including one or more Rubisco-binding motifs (RBMs) and a heterologous polypeptide. Further aspects of the present disclosure relate to genetically altered plants having a stabilized polypeptide including two or more RBMs and one or both of an algal Rubisco-binding membrane protein (RBMP) and a Rubisco small subunit (SSU) protein. Other aspects of the present disclosure relate to methods of making such chimeric polypeptides and plants, as well as cultivating these genetically altered plants.
Type:
Application
Filed:
July 30, 2020
Publication date:
September 1, 2022
Applicants:
The Trustees of Princeton University, The Board of Trustees of the Leland Stanford Junior University, University of York, Howard Hughes Medical Institute
Inventors:
Martin C. Jonikas, Moritz Meyer, Shan He, Alan Itakura, Vivian Chen Wong, Luke Colin Martin Mackinder, Zhiheng Yu, Doreen Matthies, Hui-Ting Chou
Abstract: Embodiments herein describe systems and methods to identify and treat pancreatic ductal adenocarcinoma (PDAC) based on cell of origin. Various embodiments comprise assessing transcriptomic data to identify gene expression profiles for the cancer. Based on type of cancer, additional embodiments treat individuals for PDAC. Further embodiments identify possible treatments for a PDAC tumor, by screening effective treatments, including drugs.
Type:
Application
Filed:
March 1, 2022
Publication date:
September 1, 2022
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Laura D. Attardi, Christina Curtis, Brittany M. Flowers, Hang Xu, Jose A. Seoane Fernandez
Abstract: Methods, devices, compositions and kits are provided for analysis of the microbiome or individual components thereof in an individual. The methods find use in a determination of infection, in analysis of the microbiome structure, in determining the immunocompetence of an individual, and the like. In some embodiments of the invention, the individual is treated with an therapeutic regimen, e.g. drugs, diet, radiation therapy, and the like.
Type:
Grant
Filed:
June 14, 2021
Date of Patent:
August 30, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Iwijn de Vlaminck, Michael Kertesz, Kiran Kaur Khush, Mark Alec Kowarsky, Lance Martin, Stephen R. Quake, Hannah Valantine
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
August 30, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.
Type:
Application
Filed:
August 11, 2021
Publication date:
August 25, 2022
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Helen M. Blau, Adelaida R. Palla, Andrew Tri Van Ho
Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.
Type:
Grant
Filed:
July 30, 2019
Date of Patent:
August 23, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf, Aaron Michael Ring, Akanksha Chhabra, Peter Schnorr
Abstract: The present disclosure is directed to chimeric antigen receptors binding to Glypican 2, nucleic acids encoding the same, and cells expressing the same, and methods of using such cells to treat cancers that express or overexpress the Glypican 2 antigen.
Type:
Application
Filed:
July 17, 2020
Publication date:
August 18, 2022
Applicants:
The Children's Hospital of Philadelphia, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Kristopher BOSSE, John MARIS, David BARRETT, Jessica FOSTER, Dimiter DIMITROV, Crystal MACKALL, Robbie MAJZNER, ZHONGYU ZHU, Sabine HEITZENEDER, Dontcho V. JELEV
Abstract: Systems and methods for generating RNA nanostructures capable of linking RNA structures and capable of securing aptamers in an active and stable structure are disclosed. Generally, RNA possesses many structural properties to create novel nanostructures and machines. RNA tertiary structure is composed of discrete and recurring components known as tertiary ‘motifs’. Along with the helices that they interconnect, many of these structural motifs appear highly modular. Systems and methods herein generate a motif library including canonical and noncanonical motifs to design a candidate path to connect one or more RNA molecules. These paths can also be used to secure RNA aptamers to improve aptamer stability and activity.
Type:
Application
Filed:
April 20, 2020
Publication date:
August 18, 2022
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Rhiju Das, Joseph Yesselman, Kalli Kappel
Abstract: A system and method for analyzing a plurality of tissue image samples at different stages of image processing in order to establish the level of fibrosis within a patient from which the tissue image sample was retrieved. Various embodiments incorporate machine learning techniques which enable an automated progressive approach to effectively and efficiently diagnosing fibrotic conditions based on tissue image samples.
Type:
Application
Filed:
July 27, 2020
Publication date:
August 18, 2022
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Shamik Mascharak, Heather E. desJardins-Park, Mimi Borrelli, Alessandra Laura Moore, Michael T. Longaker
Abstract: The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.
Type:
Grant
Filed:
May 18, 2018
Date of Patent:
August 16, 2022
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: Machine learning analysis of mass spectrometry spectra from human sweat samples is used to determine characteristics of interest such as age, ethnicity, gender drug use and disease state directly from the m/z data. This avoids the difficult problem of performing a full chemical analysis of human sweat samples to determine the characteristics of interest.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
August 16, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.
Type:
Application
Filed:
December 29, 2021
Publication date:
August 11, 2022
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
David M. Kurtz, Maximilian Diehn, Arash Ash Alizadeh
Abstract: Methods for treating a cancer are provided, the methods comprising administering to an individual an effective amount of a hypoxia targeting composition, such as a hypoxia-activated drug or a prodrug thereof, and combinations thereof with an effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor. In some instances, one or more of a homology recombination (HR) efficiency status, an IDH mutation status, and a hypoxia status of a cancer is used as a basis for selecting an individual for a treatment disclosed herein. Also provided are compositions (such as pharmaceutical formulations), medicine, kits, and unit dosages useful for the methods described herein.
Type:
Application
Filed:
December 6, 2019
Publication date:
August 11, 2022
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Various aspects as described herein are directed to a radiative cooling device and method for cooling an object. As consistent with one or more embodiments, a radiative cooling device includes a solar spectrum reflecting structure configured and arranged to suppress light modes, and a thermally-emissive structure configured and arranged to facilitate thermally-generated electromagnetic emissions from the object and in mid-infrared (IR) wavelengths.
Type:
Grant
Filed:
March 8, 2021
Date of Patent:
August 9, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Aaswath Pattabhi Raman, Shanhui Fan, Eden Rephaeli
Abstract: Exemplary aspects are directed to a power-amplification circuit including multiple in-parallel circuit paths, each including a power amplifier driving an immittance converter. Current from each output of the respective immittance converters is combined for delivery to a load. In a more specific example, a control circuit may be used to modulate, such as by enabling or disabling power delivered from, one or more of the power amplifiers for fast, coarse resetting of the overall power delivered to the load, and/or to modulate one or more of the modulate immittance converters (e.g., via a phase or signal-timing adjustment) to finely tune the resetting of the overall power delivered to the load. Using the control circuit for providing both the coarse adjustment and the fine adjustment, and fast acting precise delivery of overall power delivered to a load may be realized for any of a variety of applications.
Type:
Grant
Filed:
July 17, 2020
Date of Patent:
August 9, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Kawin Surakitbovorn, Juan Rivas-Davila, Lei Gu
Abstract: Systems and methods for deep brain stimulation using kinematic feedback in accordance with embodiments of the invention are illustrated. One embodiment includes a deep brain stimulation system, including an implantable neurostimulator, a first inertial measurement unit (IMU), a second IMU, and a controller, where the controller is communicatively coupled to the implantable neurostimulator, the first IMU, and the second IMU, and where the controller is configured to obtain kinematic data from the first IMU and the second IMU, identify an abnormal movement event based on the kinematic data, and modify deep brain stimulation provided by the implantable neurostimulator based on the identified abnormal movement event.
Type:
Application
Filed:
February 1, 2022
Publication date:
August 4, 2022
Applicants:
The Board of Trustees of the Leland Stanford Junior University, University of Washington
Inventors:
Helen Bronte-Stewart, Yasmine Kehnemouyi, Matthew Petrucci, Jeffrey Herron, Johanna O'Day
Abstract: Provided herein are rechargeable alkali metal batteries comprising: an anode including an alkali metal; a cathode; and an electrolyte to support reversible plating and stripping of the alkali metal at the anode, wherein the electrolyte includes alkali metal ions, chloroaluminate anions (AlClri), and an additive including imide anions.
Type:
Application
Filed:
July 2, 2020
Publication date:
August 4, 2022
Applicant:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Hongjie DAI, Hao SUN, Guanzhou ZHU, Yuanyao LI
Abstract: Systems and methods for deep brain stimulation using beta burst feedback in accordance with embodiments of the invention are illustrated. One embodiment includes a deep brain stimulation system, including a neurostimulator, and a controller, where the controller is communicatively coupled to the neurostimulator and configured to obtain a plurality of neural activity signals from the neurostimulator, identify beta bursts within each neural activity signal, classify identified beta bursts as pathological or normal, and modify stimulation provided by the neurostimulator based on the classified beta bursts.
Type:
Application
Filed:
February 1, 2022
Publication date:
August 4, 2022
Applicants:
The Board of Trustees of the Leland Stanford Junior University, University of Washington
Inventors:
Helen Bronte-Stewart, Matthew Petrucci, Ross Anderson, Raumin Neuville, Jordan Parker, Jeffrey Herron
Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?cheterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
Type:
Grant
Filed:
June 23, 2020
Date of Patent:
August 2, 2022
Assignees:
University of Washington, The Board of Trustees of the Leland Stanford Junior University
Inventors:
Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey
Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
August 2, 2022
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera